Remember
 
+
 
+
 Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
 
russurban Followed KIQ5 hours ago
russurban Placed a 'Buy' Sentiment on VXRTMore than a week ago
russurban Placed a 'Buy' Sentiment on OTLKMore than a week ago
anonusers Placed a 'Sell' Sentiment on UNVC4 days ago
anonusers Placed a 'Buy' Sentiment on HOMEMore than a week ago
anonusers Placed a 'Sell' Sentiment on WBAMore than a week ago
stockarticles Placed a 'Buy' Sentiment on BBMore than a week ago
stockarticles Followed BBMore than a week ago
stockarticles Placed a 'Buy' Sentiment on SNAPMore than a week ago
 
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  VXRT  •  OTLK  •  PINS  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  •  IRBT

     
 

September 16, 2009

SpeculatingStocks.com Stock Pick: GenVec, Inc. (GNVC)

Stock Price: $0.81


GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer.

GNVC's lead product, TNFerade(TM) is currently in a Phase III study for locally advanced pancreatic cancer. TNFerade(TM) is also being explored for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer.

GNVC just received notification from the NASDAQ that they must meet or exceed $1.00 per share for at least ten consecutive business days. We believe GNVC will be able to meet this requirement. The company has 180 calendar days to regain compliance. GNVC is up from its lows below $0.35 earlier in the year.

GNVC has seen a nice amount of interest over the last six trading days between $0.76 and $0.86. Volume has been strong for GNVC. However, we believe GNVC is still under the radar with only a 12.80% institutional interest and trading at a market cap of only around $80 million.

GNVC's management team has significant experience. GNVC has around $12.6 million in cash, cash equivalents and short-term investments.

 
     
Untitled Document